🚀 VC round data is live in beta, check it out!
Largest Biopharmaceuticals Public Companies
Benchmark revenue and EBITDA valuation multiples for public comps like
Eli Lilly, Johnson & Johnson, AbbVie, Roche and AstraZeneca.
 | $939 | +5% | $839B | $875B | 12.5x | 26.9x | ||
| $238 | +53% | $574B | $602B | 6.3x | 16.9x | ||
| $208 | +7% | $368B | $430B | 6.8x | 16.2x | ||
 | $50 | +22% | $319B | $341B | 4.3x | 10.8x | ||
 | $205 | +42% | $317B | $341B | 5.7x | 16.3x | ||
| $121 | +43% | $300B | $335B | 5.1x | 12.2x | ||
| $154 | +29% | $294B | $318B | 5.8x | 13.9x | ||
| $351 | +21% | $189B | $235B | 6.3x | 12.6x | ||
| $139 | +30% | $173B | $188B | 6.3x | 11.9x | ||
 | $37 | -44% | $165B | $181B | 3.8x | 7.9x | ||
| $27 | +10% | $153B | $203B | 3.3x | 8.4x | ||
| $59 | +17% | $120B | $156B | 3.3x | 9.0x | ||
| $29 | +48% | $117B | $137B | 3.0x | 8.9x | ||
 | $47 | -14% | $113B | $127B | 2.3x | 7.8x | ||
| $436 | -14% | $111B | $106B | 8.7x | 19.6x | ||
 | $54 | +5% | $90B | $83B | 10.1x | 19.6x | ||
| $749 | +25% | $79B | $73B | 5.0x | 14.0x | ||
 | $323 | +73% | $61B | $61B | 6.5x | 19.1x | ||
 | $131 | -7% | $57B | $68B | 2.8x | 9.7x | ||
| $36 | +32% | $57B | $83B | 2.9x | 10.6x | ||
 | $8 | +13% | $56B | $50B | 10.4x | 35.8x | ||
| $797 | +23% | $50B | $45B | 9.5x | 32.5x | ||
| Pet Care+1 | $118 | -25% | $50B | $56B | 5.9x | 13.5x | |
 | $98 | -45% | $48B | $58B | 3.7x | 10.6x | ||
| $47 | +77% | $46B | $80B | 1.5x | 7.1x | ||
| $652 | -13% | $46B | $50B | 5.8x | 18.3x | ||
| $322 | +22% | $43B | $41B | 9.8x | 49.5x | ||
 | $18 | -10% | $43B | $40B | 6.4x | 21.7x | ||
| $84 | +85% | $37B | $40B | 3.6x | 16.3x | ||
 | $31 | +106% | $36B | $50B | 2.9x | 9.4x | ||
| $25 | +17% | $36B | $33B | 5.8x | 45.6x | ||
| $67 | +53% | $35B | $33B | 2.1x | 9.2x | ||
| $155 | +115% | $33B | $33B | 35.6x | (31.7x) | ||
| $17 | -24% | $32B | $30B | 2.2x | 11.0x | ||
| $5 | +61% | $30B | $25B | 11.2x | 28.0x | ||
 | $135 | +27% | $29B | $31B | 10.3x | 27.7x | ||
| $16 | +82% | $29B | $32B | 2.4x | 8.4x | ||
| $173 | +43% | $25B | $28B | 2.9x | 9.2x | ||
| $572 | +89% | $25B | $22B | 6.8x | 12.9x | ||
| $96 | -8% | $24B | $7B | 2.3x | (5.8x) | ||
| $48 | +46% | $21B | $28B | 8.6x | 9.3x | ||
| $51 | +79% | $20B | $16B | 7.9x | (5.6x) | ||
| $28 | +143% | $20B | $16B | 1349.4x | (13.5x) | ||
| $11 | +65% | $19B | $17B | 8.7x | 66.1x | ||
| $96 | +53% | $19B | $16B | 3.0x | 9.6x | ||
| $96 | +139% | $19B | $17B | 1134.5x | (13.3x) | ||
| $44 | +7% | $18B | $18B | 53.4x | (475.6x) | ||
| $21 | +40% | $18B | $14B | 4.5x | 10.7x | ||
| $28 | +33% | $17B | $21B | 5.4x | 17.7x | ||
| $200 | +70% | $17B | $16B | 3.5x | 9.0x | ||
| $18 | +60% | $16B | $16B | 30.0x | (337.4x) | ||
| $13 | +60% | $16B | $29B | 2.0x | 6.9x | ||
| $20 | -18% | $15B | $15B | 6301.8x | (14.9x) | ||
 | $44 | +39% | $15B | $16B | 5.1x | 13.0x | ||
| $45 | +24% | $15B | $15B | 10.5x | 32.0x | ||
| $239 | +40% | $15B | $15B | 14.0x | 293.2x | ||
| $63 | +48% | $15B | $14B | 43.0x | (418.8x) | ||
| $75 | +94% | $14B | $16B | 25.4x | (35.3x) | ||
| $8 | -3% | $14B | $12B | 2.1x | 14.6x | ||
 | $29 | +1725% | $14B | $14B | — | — | ||
| $1 | +51% | $14B | $13B | 2.6x | 10.1x | ||
| $1 | +51% | $14B | $12B | 3.1x | 11.6x | ||
| $22 | -26% | $13B | $13B | 9.1x | 26.9x | ||
| $244 | +3% | $13B | $13B | 62.5x | 101.3x | ||
| $129 | +20% | $13B | $12B | 3.9x | 16.3x | ||
| $75 | +145% | $12B | $12B | 13.0x | (28.6x) | ||
 | $86 | +35% | $12B | $12B | 5.4x | 14.8x | ||
| $194 | +66% | $12B | $15B | 3.5x | 14.0x | ||
| $520 | +56% | $12B | $11B | 10.2x | — | ||
| $265 | +82% | $12B | $12B | — | — | ||
 | $57 | -4% | $12B | $14B | 4.5x | 12.0x | ||
| $23 | +144% | $12B | $15B | 3.1x | 16.3x | ||
| $44 | +13% | $11B | $11B | 4.4x | 10.5x | ||
| $25 | +11% | $11B | $11B | 3.9x | 13.7x | ||
| $13 | +3% | $11B | $11B | 2.9x | 12.8x | ||
| $13 | -21% | $11B | $10B | 3.1x | 14.8x | ||
| $55 | -14% | $10B | $10B | 2.9x | 13.7x | ||
| $9 | +55% | $10B | $10B | 14.7x | — | ||
| $8 | +72% | $10B | $9B | 9.6x | 30.8x | ||
| $10 | +2% | $10B | $10B | 3.5x | 13.3x | ||
| $18 | +185% | $10B | $10B | 15.9x | 46.1x | ||
| $123 | +1567% | $10B | $9B | 1834.7x | (34.0x) | ||
| $4 | +17% | $10B | $13B | 2.1x | 11.4x | ||
| $5 | -6% | $9B | $9B | 1.3x | 10.4x | ||
| $22 | -16% | $9B | $10B | 6.3x | 25.5x | ||
| $8 | +32% | $9B | $9B | — | — | ||
| $369 | -- | $9B | $9B | 7.8x | 29.4x | ||
| $65 | +369% | $9B | $9B | 13.5x | (87.7x) | ||
| $178 | +59% | $9B | $9B | 12.3x | (70.4x) | ||
| $32 | +22% | $9B | $8B | 1.6x | 13.5x | ||
| $17 | -45% | $9B | $17B | 1.5x | 7.6x | ||
| $316 | +748% | $9B | $8B | 4929.3x | (23.0x) | ||
| $61 | +70% | $9B | $7B | — | (7.5x) | ||
 | $281 | +40% | $9B | $8B | 3.2x | 11.8x | ||
| $16 | +15% | $8B | $7B | 2.2x | 8.2x | ||
| $14 | +9% | $8B | $8B | 2.3x | 11.2x | ||
| $103 | +34% | $8B | $7B | 1737.3x | (16.4x) | ||
| $68 | +10% | $8B | $10B | 6.7x | 12.5x | ||
| $65 | +52% | $8B | $8B | 94.4x | (13.1x) | ||
| $5 | -5% | $8B | $7B | 2.7x | 14.4x |
Financial data powered by FactSet and Morningstar. Valuation multiples as of last 12 months. For more data, start your free trial here.
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.